Tetraphase制药

TTPH NASDAQ
0.6805
-0.0475
-6.52%
已收盘, 16:23 06/14 EDT
开盘
0.7213
昨收
0.7280
最高
0.7573
最低
0.6600
成交量
68.09万
成交均量(3M)
58.53万
52周最高
4.350
52周最低
0.6600
换手率
1.25%
市值
3,692.65万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Tetraphase制药 TTPH股票价格,Tetraphase制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
展开 >

最近浏览

名称
价格
涨跌幅